INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • March 1st, 2017 • ULURU Inc. • Pharmaceutical preparations • New York
THIS INVESTOR RIGHTS AGREEMENT (this “Agreement”), is made as of the 27th day of February, 2017, by and among ULURU Inc., a Nevada corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.
ULURU INC. NOTE, WARRANT, AND PREFERRED STOCK PURCHASE AGREEMENTNote, Warrant, and Preferred Stock Purchase Agreement • March 1st, 2017 • ULURU Inc. • Pharmaceutical preparations • New York
THIS NOTE, WARRANT, AND PREFERRED STOCK PURCHASE AGREEMENT (this “Agreement”), is made as of the 27th day of February, 2017 by and among ULURU Inc., a Nevada corporation (the “Company”), Velocitas Partners, LLC, a Delaware limited liability company (“Velocitas”), and the investors listed on Exhibit A attached to this Agreement (each a “Purchaser” and together with Velocitas, the “Purchasers”).
BACKSTOP AGREEMENTBackstop Agreement • March 1st, 2017 • ULURU Inc. • Pharmaceutical preparations • New York
This BACKSTOP AGREEMENT (this “Agreement”) is entered into as of February 27, 2017 (the “Effective Date”) by and between ULURU INC., a Nevada corporation (the “Company”), Bradley J. Sacks (“Buyer”) and Velocitas Partners LLC (“Velocitas”).
SECURITY AGREEMENTSecurity Agreement • March 1st, 2017 • ULURU Inc. • Pharmaceutical preparations • New York
THIS SECURITY AGREEMENT (this “Security Agreement”) is entered into effective as of February 27, 2017, by and between Velocitas Partners LLC, a Delaware limited liability company (together with its successors and/or assigns, the “Lender”), ULURU INC., a Nevada corporation (the “Borrower”), Cardinia Acquisition Corp., a Delaware corporation (“Cardinia”) and ULURU Delaware Inc. (“ULULU DE”, and together with the Borrower and Cardinia, the “Borrower Entities”).
VOTING AGREEMENTVoting Agreement • March 1st, 2017 • ULURU Inc. • Pharmaceutical preparations • New York
THIS VOTING AGREEMENT (this “Agreement”), is made and entered into as of this 27th day of February, 2017, by and among ULURU, Inc., a Nevada corporation (the “Company”), each holder of the Company’s Series B Convertible Preferred Stock, $0.001 par value per share (the “Series B Preferred Stock”) listed on Schedule A (together with any subsequent transferees, who become parties hereto as “Investors” pursuant to Subsection 5.1, the “Investors”), and those certain stockholders of the Company listed on Schedule B (the “Key Holders,” and together collectively with the Investors, the “Stockholders”).
